Adell Harriman & Carpenter Inc. Has $5.01 Million Stock Holdings in Johnson & Johnson $JNJ

Adell Harriman & Carpenter Inc. decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 14.3% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,779 shares of the company’s stock after selling 5,487 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Johnson & Johnson were worth $5,007,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Nuveen LLC bought a new stake in Johnson & Johnson in the 1st quarter valued at $1,369,188,000. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 26.4% during the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Pacer Advisors Inc. raised its holdings in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company’s stock worth $502,509,000 after buying an additional 2,825,626 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Johnson & Johnson by 159.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 4,159,260 shares of the company’s stock worth $635,327,000 after buying an additional 2,557,388 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth about $401,420,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Performance

JNJ stock opened at $186.39 on Thursday. The stock has a market capitalization of $449.07 billion, a PE ratio of 17.99, a price-to-earnings-growth ratio of 2.20 and a beta of 0.40. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock’s 50 day simple moving average is $182.88 and its 200 day simple moving average is $167.17.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analysts Set New Price Targets

JNJ has been the subject of several recent research reports. Royal Bank Of Canada reissued an “outperform” rating and issued a $209.00 price target on shares of Johnson & Johnson in a research note on Friday, October 10th. Cowen restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Morgan Stanley set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 15th. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. Finally, Johnson Rice set a $190.00 price target on Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.